Patents Assigned to Genentech
  • COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF HEMATOPOIETIC MALIGNANCIES
    Publication number: 20130330765
    Abstract: Combinations of PI3K inhibitor compounds having Formula I and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hematopoietic malignancies. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: August 15, 2013
    Publication date: December 12, 2013
    Applicant: Genentech, Inc.
    Inventors: Allen J. Ebens, JR., Lori Friedman
  • Combinations of phosphoinositide 3-kinase inhibitor compounds chemotherapeutic agents, and methods of use
    Patent number: 8604014
    Abstract: Combinations of PI3K inhibitor compounds having Formulas I and II and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hyperproliferative disorders such as cancer. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: May 17, 2011
    Date of Patent: December 10, 2013
    Assignees: Genentech, Inc., F. Hoffmann-La Roche AG
    Inventors: Marcia Belvin, Lori Friedman, Klaus Hoeflich, Deepak Sampath, Ulka Vijapurkar, Jeffrey Wallin, Leisa Johnson, Mallika Singh, Sonal Patel
  • Inhibitors of angiopoietin-like 4 protein, combinations, and their use
    Patent number: 8604185
    Abstract: Modulators of angiopoietin-like 4 protein are provided along with methods for their use in the treatment of diseases and pathological conditions. Combinations of ANGPTL4 antagonists and other therapeutics, e.g., anti-cancer agents, and methods of their use in the treatment of mammals susceptible to or diagnosed with cancer, or with relapse tumor growth or relapse cancer cell growth are also provided.
    Type: Grant
    Filed: June 21, 2010
    Date of Patent: December 10, 2013
    Assignee: Genentech, Inc.
    Inventors: Hanspeter Gerber, Napoleone Ferrara, Xiao Huan Liang
  • Methods and compositions for targeting polyubiquitin
    Patent number: 8603475
    Abstract: Anti-polyubiquitin monoclonal antibodies, and methods for using the antibodies, are provided.
    Type: Grant
    Filed: April 23, 2010
    Date of Patent: December 10, 2013
    Assignee: Genentech, Inc.
    Inventors: Nathaniel C. Gordon, Robert F. Kelley, Anh Pham
  • Adjuvant therapy with an anti-ERBB2 antibody conjugated to a maytansiniod
    Patent number: 8597654
    Abstract: The present application describes adjuvant therapy of nonmetastatic breast cancer using an anti-ErbB2 antibody conjugated to a maytansinoid.
    Type: Grant
    Filed: August 8, 2011
    Date of Patent: December 3, 2013
    Assignee: Genentech, Inc.
    Inventor: John L. Bryant
  • Multispecific anti-HER antibodies
    Patent number: 8597652
    Abstract: The invention provides anti-HER antibodies, including multispecific anti-HER antibodies, compositions comprising and methods of using these antibodies. Also provided herein are EGFR/HER3 multispecific antibodies that are less toxic than traditional EGFR antagonists.
    Type: Grant
    Filed: March 19, 2010
    Date of Patent: December 3, 2013
    Assignee: Genentech, Inc.
    Inventors: Germaine Fuh, Lauric Haber, Gabriele Schaefer, Mark X. Sliwkowski
  • N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF
    Publication number: 20130317001
    Abstract: The invention provides novel compounds having the general formula: and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X2, L, subscript m, X1, B, R1, R2, R3, R4, R5 and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: May 21, 2013
    Publication date: November 28, 2013
    Applicants: XENON PHARMACEUTICALS INC., GENENTECH, INC.
    Inventors: Jean-Christophe Andrez, Sultan Chowdhury, Shannon Marie Decker, Christoph Martin Dehnhardt, Thilo Focken, Michael Edward Grimwood, Ivan William Hemeon, Qi Jia, Jun Li, Daniel F. Ortwine, Brian Safina, Tao Sheng, Shaoyi Sun, Daniel P. Sutherlin, Michael Scott Wilson, Alla Yurevna Zenova
  • ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR
    Publication number: 20130316402
    Abstract: Anti-STEAP-1 antibodies and immunoconjugates thereof are provided. Methods of using anti-STEAP-1 antibodies and immunoconjugates thereof are provided.
    Type: Application
    Filed: February 13, 2013
    Publication date: November 28, 2013
    Applicant: GENENTECH, INC.
    Inventors: Mark S. Dennis, Bonnee Rubinfeld, Paul Polakis, Aya Jakobovits
  • N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF
    Publication number: 20130317000
    Abstract: The invention provides novel compounds having the general formula: and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X2, L, subscript m, X1, B, R1, R2, R3, R4, R5 and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: May 21, 2013
    Publication date: November 28, 2013
    Applicants: XENON PHARMACEUTICALS INC., GENENTECH, INC
    Inventors: Sultan Chowdhury, Christoph Martin Dehnhardt, Thilo Focken, Michael Edward Grimwood, Ivan William Hemeon, Qi Jia, Daniel Ortwine, Brian Safina, Shaoyi Sun, Daniel P. Sutherlin, Alla Yurevna Zenova
  • ANTI-VEGF ANTIBODIES
    Publication number: 20130315918
    Abstract: Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.
    Type: Application
    Filed: June 27, 2013
    Publication date: November 28, 2013
    Applicant: Genentech, Inc.
    Inventors: GERMAINE FUH, HANS-PETER GERBER, WEI-CHING LIANG, FREDERIC FELLOUSE, SACHDEV S. SIDHU, CHRISTIAN WIESMANN
  • HUMANIZED ANTI-CD40 ANTIBODIES CONJUGATED TO THERAPEUTIC AGENTS
    Publication number: 20130315900
    Abstract: Provided are humanized anti-CD40 antibodies and antigen-binding fragments and methods for treating disease characterized by expression of CD40 antigen.
    Type: Application
    Filed: June 25, 2013
    Publication date: November 28, 2013
    Applicants: Seattle Genetics, Inc., Genentech, Inc.
    Inventors: Leonard G. Presta, Lori Y. O'Connell, Svetlana O. Doronina
  • Gene detection assay for improving the likelihood of an effective response to an EGFR antagonist cancer therapy
    Patent number: 8592152
    Abstract: The invention provides a method for more effective treatment of patients susceptible to or diagnosed with tumors overexpressing EGFR, as determined by a gene amplification assay, with an EGFR antagonist. Such method comprises administering a cancer-treating dose of the EGFR antagonist, preferably in addition to chemotherapeutic agents, to a subject in whose tumor cells erbB1 gene has been found to be amplified e.g., by fluorescent in situ hybridization. EGFR antagonists described include an anti-EGFR antibody.
    Type: Grant
    Filed: October 14, 2011
    Date of Patent: November 26, 2013
    Assignee: Genentech, Inc.
    Inventor: Robert D. Mass
  • Anti-ERBB2 antibody adjuvant therapy
    Patent number: 8591897
    Abstract: The present application describes adjuvant therapy of nonmetastatic breast cancer using HERCEPTIN®.
    Type: Grant
    Filed: April 6, 2006
    Date of Patent: November 26, 2013
    Assignee: Genentech, Inc.
    Inventor: John L. Bryant
  • INHIBITION OF IL-17 PRODUCTION
    Publication number: 20130309194
    Abstract: The invention concerns inhibition of the production of proinflammatory cytokine interleukin-17 (IL-17) by T cells, using an antagonist of interleukin-23 (IL-23). The invention further concerns the use of IL-23 antagonists in the treatment of inflammatory diseases characterized by the presence of elevated levels of IL-17. IL-23 antagonists include, without limitation, antibodies specifically binding to a subunit or IL-17 or an IL-17 receptor. The invention additionally concerns induction of IL-7 production by using an IL-23 agonist.
    Type: Application
    Filed: October 11, 2012
    Publication date: November 21, 2013
    Applicant: GENENTECH, INC.
    Inventor: Austin L. Gurney
  • ANTI-INTERFERON-ALPHA ANTIBODIES
    Publication number: 20130309236
    Abstract: The present invention relates generally to the generation and characterization of neutralizing anti-IFN-? monoclonal antibodies with broad reactivity against various IFN-? subtypes. The invention further relates to the use of such anti-IFN-? antibodies in the diagnosis and treatment of disorders associated with increased expression of TUN-?, in particular, autoimmune disorders such as insulin-dependent diabetes mellitus (IDDM) and systemic lupus erythematosus (SLE).
    Type: Application
    Filed: July 31, 2013
    Publication date: November 21, 2013
    Applicant: Genentech, Inc.
    Inventors: Anan CHUNTHARAPAI, Jin K. Kim, Leonard G. Presta, Timothy Stewart
  • HIGH-CONCENTRATION MONOCLONAL ANTIBODY FORMULATIONS
    Publication number: 20130309226
    Abstract: The present application discloses high-concentration monoclonal antibody formulations suitable for subcutaneous administration, e.g. via a pre-filled syringe. In particular, it discloses a formulation comprising a spray dried monoclonal antibody at a concentration of about 200 mg/mL or more suspended in a non-aqueous suspension vehicle where the viscosity of the suspension vehicle is less than about 20 centipoise. Also disclosed are: a subcutaneous administration device with the formulation therein, a method of making the formulation, a method of making an article of manufacture comprising the suspension formulation, use of the formulation in the preparation of a medicament, and a method of treating a patient with the formulation.
    Type: Application
    Filed: May 17, 2013
    Publication date: November 21, 2013
    Applicant: Genentech, Inc.
    Inventors: Nicholas J. Armstrong, Mayumi N. Bowen, Yuh-Fun Maa
  • Benzoxazepin PI3K inhibitor compounds and methods of use
    Patent number: 8586574
    Abstract: Benzoxazepin compounds of Formula I, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z1 is CR1 or N; Z2 is CR2 or N; Z3 is CR3 or N; Z4 is CR4 or N; and B is a pyrazolyl, imidazolyl, or triazolyl ring fused to the benzoxepin ring, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: November 20, 2012
    Date of Patent: November 19, 2013
    Assignee: Genentech, Inc.
    Inventors: Nicole Blaquiere, Steven Do, Danette Dudley, Adrian Folkes, Robert Heald, Timothy Heffron, Mark Jones, Aleksandr Kolesnikov, Chudi Ndubaku, Alan G. Olivero, Stephen Price, Steven Staben, Lan Wang
  • Methods of using apoptotic anti-IGE antibodies
    Patent number: 8586040
    Abstract: The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders.
    Type: Grant
    Filed: October 25, 2011
    Date of Patent: November 19, 2013
    Assignee: Genentech, Inc.
    Inventors: Lawren Wu, Mercedesz Balazs, Hans Brightbill, Andy Chan, Yvonne Chen, Anan Chuntharapai, Mark Dennis, Terence Wong
  • PREVENTION AND TREATMENT OF COMPLEMENT-ASSOCIATED EYE CONDITIONS
    Publication number: 20130302333
    Abstract: The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists.
    Type: Application
    Filed: June 27, 2013
    Publication date: November 14, 2013
    Applicant: GENENTECH, INC.
    Inventors: Philip Hass, Yin Jianping, Kenneth Katschke, JR., Micah Steffek, Christian Weismann, Menno Van Lookeren Campagne
  • Subcutaneously administered anti-IL-6 receptor antibody
    Patent number: 8580264
    Abstract: The present application discloses methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed.
    Type: Grant
    Filed: November 7, 2011
    Date of Patent: November 12, 2013
    Assignees: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Xiaoping Zhang, Min Bao, Angelika M. Jahreis, Kimio Terao